This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Mirati Therapeutics Dividende

Dividende contrôle des critères 0/6

Mirati Therapeutics does not have a record of paying a dividend.

Informations clés

n/a

Rendement du dividende

n/a

Ratio de distribution

Rendement moyen de l'industrie	1.9%
Prochaine date de paiement du dividende	n/a
Date ex-dividende	n/a
Dividende par action	n/a
Résultat par action	-US$10.35
Prévision de rendement du dividende	0%

Mises à jour récentes des dividendes

Pas de mise à jour

Recent updates

We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

Oct 05

Is Mirati Therapeutics (NASDAQ:MRTX) In A Good Position To Invest In Growth?

Jun 22

Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

May 17

We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

Feb 01

Some Analysts Just Cut Their Mirati Therapeutics, Inc. (NASDAQ:MRTX) Estimates

Dec 09

We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth

Oct 08

Is There An Opportunity With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) 30% Undervaluation?

Sep 11

Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

Aug 08

Mirati: Not Looking Good In 2022, But Stronger Prospects In 2-3 Years

Jun 21

Stabilité et croissance des paiements

Récupération des données sur les dividendes

Dividende stable: Insufficient data to determine if MRTX's dividends per share have been stable in the past.

Dividende croissant: Insufficient data to determine if MRTX's dividend payments have been increasing.

Rendement des dividendes par rapport au marché

Mirati Therapeutics Rendement des dividendes par rapport au marché

Comment le rendement du dividende de MRTX se compare-t-il à celui du marché ?
Segment	Rendement du dividende
Entreprise (MRTX)	n/a
25% du marché (US)	1.4%
25% du marché (US)	4.3%
Moyenne du secteur (Biotechs)	1.9%
Analyste prévisionnel (MRTX) (jusqu'à 3 ans)	0%

Dividende notable: Unable to evaluate MRTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Dividende élevé: Unable to evaluate MRTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Bénéfice distribué aux actionnaires

Couverture des revenus: Insufficient data to calculate MRTX's payout ratio to determine if its dividend payments are covered by earnings.

Paiement en espèces aux actionnaires

Couverture des flux de trésorerie: Unable to calculate sustainability of dividends as MRTX has not reported any payouts.

This company has been acquired

Mirati Therapeutics Dividende

Dividende contrôle des critères 0/6

Informations clés

Mises à jour récentes des dividendes

Recent updates

Mirati Therapeutics, Inc. Files Form 15

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from NASDAQ Biotechnology Index

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders.

Mirati Therapeutics, Inc. Receives Positive Opinion from CHMP for KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation Following a Re-Examination Procedure

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Mirati Therapeutics, Inc. Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Price target increased by 9.7% to US$60.00

Sanofi Reportedly Explores Potential Acquisition of Mirati Therapeutics

New major risk - Share price stability

We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

Mirati Therapeutics, Inc. Announces CFO Changes Effective as of September 8, 2023

Insufficient new directors

Mirati Therapeutics, Inc. Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers Through Novel Approach to MTA-Cooperative PRMT5 Inhibition

Second quarter 2023 earnings: EPS exceeds analyst expectations

Mirati Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Mirati Therapeutics Provides Update on Regulatory Review in the European Union of Krazati (Adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with A Krasg12c Mutation

Price target decreased by 8.0% to US$60.64

New minor risk - Insider selling

Mirati Therapeutics Appoints Carol Gallagher, Pharm.D. as New Independent Director

Is Mirati Therapeutics (NASDAQ:MRTX) In A Good Position To Invest In Growth?

Chief Financial Officer recently sold US$172k worth of stock

Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO(R)

Insufficient new directors

Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

Consensus revenue estimates increase by 23%

Consensus revenue estimates decrease by 28%

Mirati Therapeutics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

CEO & Director recently sold US$135k worth of stock

Mirati Therapeutics, Inc. Announces U.S. Food and Drug Administration Clears the Investigational New Drug (Ind) Application of MRTX1133

Founder recently sold US$170k worth of stock

Executive VP & Chief Scientific Officer recently sold US$104k worth of stock

Mirati announces Adagrasib (KRAZATI™) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b/2 Data from Adagrasib With or Without Cetuximab in Colorectal Cancer

Mirati Therapeutics, Inc. Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Some Analysts Just Cut Their Mirati Therapeutics, Inc. (NASDAQ:MRTX) Estimates

Price target decreased to US$91.40

Executive VP & Chief Scientific Officer recently sold US$156k worth of stock

Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Mirati Therapeutics, Inc. Announces Update for the Phase 3 SAPPHIRE Study

Founder exercised options and sold US$5.7m worth of stock

Mirati Therapeutics Reportedly Seen as Takeover Target Once Again

Consensus revenue estimates increase by 48%

Mirati Therapeutics, Inc. Announces Management Changes

Mirati Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth

Is There An Opportunity With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) 30% Undervaluation?

Mirati: A Potential Blockbuster Stock, Will Need Patience

Mirati Therapeutics, Inc. Presents Late-Breaking Adagrasib Monotherapy and Combination

Mirati jumps 11% as Amgen meets key goal for rival cancer drug

Independent Director notifies of intention to sell stock

Consensus revenue estimates increase by 15%

Mirati gains as Amgen posts new combination data for rival cancer drug

Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

Mirati Therapeutics, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Mirati: Not Looking Good In 2022, But Stronger Prospects In 2-3 Years

Mirati Therapeutics, Inc. Announces Results of A Prospective Analysis from the Phase 1B Cohort of the KRYSTAL-1

Stabilité et croissance des paiements

Rendement des dividendes par rapport au marché

Bénéfice distribué aux actionnaires

Paiement en espèces aux actionnaires

Découvrir des entreprises qui versent des dividendes élevés